OptionsHouse

Options Trading News

December 31, 2012  Mon 11:20 AM CT

DVAX: SEE CHART GET CHAIN FIND STRATEGIES
Dynavax Technologies plunged last month, and one investor is positioned for further bloodletting.

optionMONSTER's Depth Charge tracking program detected the purchase of about 2,100 January 2.50 puts for $0.15 against open interest of 1,458 contracts. The trade dominated activity in the drug developer, which normally sees volume of only about 440 calls and puts in a single session.

The investor now has the right to sell DVAX shares for $2.50 on expiration three weeks from now, no matter how far they decline. He or she stands to earn leveraged profits in the event of a continued decline but will lose their $0.15 if the stock doesn't drop. (See our Education section for more on put buying)

DVAX is unchanged at $2.74 in early afternoon trading. It peaked around $5 several times in recent months but gapped sharply lower on Nov. 16 after a Food and Drug Administration advisory panel voted against approval of the company's Heplisav hepatitis B vaccine. Shares traded as low as $2.22 after that event, so today's put buyer could be looking for the stock to retest that level.

Puts outnumber calls by a bearish 23-to-1 ratio so far today, according to the Depth Charge.
Share this article with your friends


OptionsHouse

TRADING WEEKLY OPTIONS

The fastest money in the market
View full report »

Premium Services

Archived Webinar

Education & Strategy

Options Academy: At the Break

So far, my articles have taken you through a logical progression of option theory and fundamental concepts of options. As of yet, I have not mentioned a single strategy and for a good reason! The actual application of a strategy should come AFTER you learn about the option product itself.

View more education articles »